Display options
Cite
Dias S, Paredes S, Ribeiro L. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. Int J Endocrinol. 2018;2018:2637418doi: 10.1155/2018/2637418.
Dias, S., Paredes, S., & Ribeiro, L. (2018). Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. International journal of endocrinology, 20182637418. https://doi.org/10.1155/2018/2637418
Dias, Sofia, et al. "Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue." International journal of endocrinology vol. 2018 (2018): 2637418. doi: https://doi.org/10.1155/2018/2637418
Dias S, Paredes S, Ribeiro L. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. Int J Endocrinol. 2018 Jan 17;2018:2637418. doi: 10.1155/2018/2637418. eCollection 2018. PMID: 29593789; PMCID: PMC5822899.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2018 Jan 17;2018:2637418. doi: 10.1155/2018/2637418. eCollection 2018.

Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.

International journal of endocrinology

Sofia Dias, Sílvia Paredes, Laura Ribeiro

Affiliations

  1. Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
  2. Department of Endocrinology, Hospital de Braga, 4710-243 Braga, Portugal.
  3. Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
  4. I3S-Instituto de Investigação e Inovação em Saúde, University of Porto, 4200-135 Porto, Portugal.

PMID: 29593789 PMCID: PMC5822899 DOI: 10.1155/2018/2637418

Abstract

Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease. Obesity and dyslipidemia are main features of metabolic syndrome, and both can present with adipose tissue dysfunction, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity, and adipogenesis. The clinical outcomes of adipose tissue modulation by these drugs, as well as differences of major importance for clinical practice between drugs of the same class, were identified. Whether solutions to these issues will be found in further adjustments and combinations between drugs already in use or necessarily in new advances in pharmacology is not known. To better understand the effect of drugs used in dyslipidemia and obesity on adipose tissue not only is challenging for physicians but could also be the next step to tackle cardiovascular disease.

References

  1. Diabetes Care. 2015 Jul;38(7):1339-46 - PubMed
  2. Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1429-45 - PubMed
  3. Biochem Biophys Res Commun. 2013 Mar 8;432(2):365-9 - PubMed
  4. Cardiovasc Diabetol. 2014 Feb 05;13:36 - PubMed
  5. Bioorg Med Chem. 2000 Dec;8(12):2689-92 - PubMed
  6. J Leukoc Biol. 2006 Apr;79(4):803-8 - PubMed
  7. Biochim Biophys Acta. 1981 Jan 26;663(1):255-65 - PubMed
  8. Exp Biol Med (Maywood). 2014 Mar;239(3):293-301 - PubMed
  9. Clin Chim Acta. 2004 Jan;339(1-2):189-94 - PubMed
  10. Metabolism. 2006 Jun;55(6):731-5 - PubMed
  11. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14564-8 - PubMed
  12. Arterioscler Thromb Vasc Biol. 2008 May;28(5):871-7 - PubMed
  13. Clin Chim Acta. 2006 Mar;365(1-2):119-24 - PubMed
  14. Arterioscler Thromb Vasc Biol. 1996 Dec;16(12):1509-15 - PubMed
  15. Int J Cardiol. 2008 Feb 29;124(2):172-8 - PubMed
  16. J Lipid Res. 2014 Dec;55(12):2532-40 - PubMed
  17. Lancet. 2004 Jun 5;363(9424):1892-4 - PubMed
  18. Biochem Biophys Res Commun. 2005 Sep 9;334(4):1092-101 - PubMed
  19. Biochem Biophys Res Commun. 2004 Oct 15;323(2):630-5 - PubMed
  20. FEBS Lett. 2001 Nov 2;507(3):357-61 - PubMed
  21. Biochem Biophys Res Commun. 2005 Aug 26;334(2):729-32 - PubMed
  22. Biochim Biophys Acta. 2014 Jul;1841(7):919-33 - PubMed
  23. Diabetes. 2011 May;60(5):1512-8 - PubMed
  24. Nutr Metab Cardiovasc Dis. 2013 Nov;23 (11):1107-14 - PubMed
  25. Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E103-E113 - PubMed
  26. Endocrinology. 2009 Dec;150(12):5262-72 - PubMed
  27. Diabetes Obes Metab. 2013 Sep;15(9):863-6 - PubMed
  28. Am J Cardiol. 2010 Oct 1;106(7):969-75 - PubMed
  29. FEBS Lett. 1987 Jan 26;211(2):169-74 - PubMed
  30. PLoS One. 2012;7(4):e34516 - PubMed
  31. Trends Endocrinol Metab. 2014 May;25(5):255-62 - PubMed
  32. Mayo Clin Proc. 1991 Jan;66(1):23-8 - PubMed
  33. Atherosclerosis. 2007 Aug;193(2):361-5 - PubMed
  34. Clin Chim Acta. 2004 Sep;347(1-2):145-50 - PubMed
  35. Am J Cardiol. 2008 Apr 17;101(8A):20B-26B - PubMed
  36. Biochem Biophys Res Commun. 2001 Jun 8;284(2):478-84 - PubMed
  37. Int J Obes Relat Metab Disord. 2004 Nov;28(11):1357-64 - PubMed
  38. Circulation. 2003 Aug 12;108(6):736-40 - PubMed
  39. Psychopharmacology (Berl). 1979;66(3):297-300 - PubMed
  40. Acta Med Scand. 1963 Jun;173:719-22 - PubMed
  41. JAMA. 2003 Dec 10;290(22):3000-2 - PubMed
  42. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1253-61 - PubMed
  43. Metabolism. 2014 Apr;63(4):456-60 - PubMed
  44. Cell Metab. 2007 Jan;5(1):47-57 - PubMed
  45. Intern Med. 2013;52(10 ):1029-34 - PubMed
  46. J Mol Endocrinol. 2004 Aug;33(1):133-43 - PubMed
  47. Mol Cell Biochem. 2001 Jan;216(1-2):71-8 - PubMed
  48. Nature. 2002 Nov 21;420(6913):333-6 - PubMed
  49. Clin Investig Arterioscler. 2014 Jul-Aug;26(4):161-7 - PubMed
  50. J Lipid Res. 2011 May;52(5):873-84 - PubMed
  51. Exp Mol Med. 2009 Jun 30;41(6):397-405 - PubMed
  52. J Biol Chem. 2008 Jun 13;283(24):16514-24 - PubMed
  53. Diabetes. 2004 May;53(5):1285-92 - PubMed
  54. Clin Chim Acta. 2005 Oct;360(1-2):133-40 - PubMed
  55. Pharmacol Rep. 2014 Oct;66(5):880-4 - PubMed
  56. Diabetes Res Clin Pract. 2005 Jan;67(1):78-83 - PubMed
  57. Pharmacology. 2002 Sep;66(1):51-6 - PubMed
  58. Acta Diabetol. 2015 Aug;52(4):727-32 - PubMed
  59. Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):635-41 - PubMed
  60. Endocr Pract. 2017 Apr;23 (Suppl 2):1-87 - PubMed
  61. Metabolism. 1995 Feb;44(2):228-33 - PubMed
  62. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 May;35(5):511-7 - PubMed
  63. Eur Rev Med Pharmacol Sci. 2011 Oct;15(10):1187-95 - PubMed
  64. J Biochem. 2009 Jun;145(6):771-81 - PubMed
  65. BMC Musculoskelet Disord. 2011 Apr 27;12(1):82 - PubMed
  66. Metab Syndr Relat Disord. 2013 Aug;11(4):251-5 - PubMed
  67. Diabetol Metab Syndr. 2015 Mar 14;7:18 - PubMed
  68. Exp Mol Pathol. 2013 Dec;95(3):325-9 - PubMed
  69. Trends Endocrinol Metab. 2009 Mar;20(2):72-7 - PubMed
  70. Biochem Pharmacol. 2006 Feb 28;71(5):646-56 - PubMed
  71. Biochem Biophys Res Commun. 2003 Sep 19;309(2):286-90 - PubMed
  72. Am J Physiol Cell Physiol. 2003 Jul;285(1):C222-35 - PubMed
  73. Circulation. 1998 Nov 10;98(19):2088-93 - PubMed
  74. Endocr Res. 2015;40(3):133-8 - PubMed
  75. Br J Pharmacol. 2016 Jun;173(11):1820-34 - PubMed
  76. Am J Physiol Endocrinol Metab. 2014 Apr 1;306(7):E808-13 - PubMed
  77. Diabetes Obes Metab. 2009 Dec;11(12):1163-72 - PubMed
  78. Pharmacol Rep. 2011;63(5):1124-36 - PubMed
  79. Jpn J Pharmacol. 1999 Aug;80(4):375-8 - PubMed
  80. Expert Rev Cardiovasc Ther. 2011 Mar;9(3):265-77 - PubMed
  81. Endokrynol Pol. 2014;65(4):275-80 - PubMed
  82. J Pharmacol Sci. 2008 May;107(1):80-9 - PubMed
  83. Diabetes Res Clin Pract. 2011 Jun;92(3):368-74 - PubMed
  84. Biochem Biophys Res Commun. 2002 Nov 1;298(3):297-302 - PubMed
  85. Free Radic Res. 2007 Sep;41(9):1028-34 - PubMed
  86. Atherosclerosis. 2008 Feb;196 (2):565-73 - PubMed
  87. Cardiovasc Diabetol. 2011 Dec 01;10:109 - PubMed
  88. Mol Cell Endocrinol. 2015 Feb 15;402:43-50 - PubMed
  89. Prostaglandins Other Lipid Mediat. 2011 Apr;94(3-4):96-103 - PubMed
  90. Exp Cell Res. 2013 Jun 10;319(10):1523-33 - PubMed
  91. FEBS Lett. 2005 Dec 19;579(30):6821-6 - PubMed
  92. J Lipid Res. 2011 Apr;52(4):657-67 - PubMed
  93. Am J Physiol Cell Physiol. 2000 Oct;279(4):C1100-6 - PubMed
  94. Science. 2001 Aug 31;293(5535):1673-7 - PubMed
  95. Cardiovasc Res. 2010 May 1;86(2):219-25 - PubMed
  96. Endocr J. 2007 Jun;54(3):431-5 - PubMed
  97. Nutrition. 2000 Oct;16(10 ):967-75 - PubMed
  98. Life Sci. 2008 Jan 2;82(1-2):85-90 - PubMed
  99. Cardiovasc Ther. 2014 Apr;32(2):40-6 - PubMed
  100. J Cell Biochem. 1998 Mar 1;68(3):298-308 - PubMed
  101. J Atheroscler Thromb. 2006 Apr;13(2):122 - PubMed
  102. Endocrine. 2014 Apr;45(3):409-21 - PubMed
  103. BMB Rep. 2009 Oct 31;42(10):679-84 - PubMed
  104. Eur J Pharmacol. 2013 Jan 5;698(1-3):292-8 - PubMed
  105. Circulation. 1999 Dec 21-28;100(25):2473-6 - PubMed
  106. Am J Med. 2017 Feb;130(2):173-187 - PubMed
  107. Pharmacol Rep. 2014 Jun;66(3):442-7 - PubMed
  108. Cell Biochem Funct. 2015 Jun;33(4):249-56 - PubMed
  109. Endocr Rev. 1999 Dec;20(6):876-913 - PubMed
  110. PLoS One. 2012;7(11):e48392 - PubMed
  111. Diabetologia. 1992 Dec;35 Suppl 2:S34-40 - PubMed
  112. J Clin Invest. 2003 Dec;112(12):1796-808 - PubMed
  113. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1213-22 - PubMed
  114. Atherosclerosis. 2010 Mar;209(1):89-95 - PubMed
  115. Br J Nutr. 1998 Dec;80(6):495-502 - PubMed
  116. Genes Dev. 1996 May 1;10(9):1096-107 - PubMed
  117. J Lipids. 2011;2011:783976 - PubMed
  118. PLoS One. 2016 Mar 17;11(3):e0151916 - PubMed
  119. PLoS One. 2013 Nov 15;8(11):e80588 - PubMed
  120. J Biol Chem. 2015 Jan 9;290(2):755-61 - PubMed
  121. Int J Nanomedicine. 2013;8:451-9 - PubMed
  122. Obesity (Silver Spring). 2008 Jun;16(6):1199-207 - PubMed
  123. Basic Res Cardiol. 2013 Mar;108(2):333 - PubMed
  124. Cell Metab. 2008 Oct;8(4):310-7 - PubMed
  125. J Biol Chem. 1998 Jun 12;273(24):14950-7 - PubMed
  126. Diabetes. 2014 Oct;63(10):3346-58 - PubMed
  127. Drug Des Devel Ther. 2015 Feb 18;9:1177-84 - PubMed
  128. Am J Physiol Endocrinol Metab. 2009 Mar;296(3):E549-58 - PubMed
  129. Arch Med Res. 2010 Feb;41(2):75-82 - PubMed
  130. Lancet. 2014 Aug 30;384(9945):766-81 - PubMed
  131. EBioMedicine. 2016 Aug;10 :185-94 - PubMed
  132. Pharmacol Ther. 2006 Sep;111(3):893-908 - PubMed
  133. Biochim Biophys Acta. 1986 Jun 27;877(2):314-21 - PubMed
  134. Biochimie. 2016 Jun;125:259-66 - PubMed
  135. Semin Cell Dev Biol. 2016 Jun;54:68-81 - PubMed
  136. Genes Dev. 2000 Jun 1;14(11):1293-307 - PubMed
  137. Science. 2004 Oct 15;306(5695):457-61 - PubMed
  138. Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2183-5 - PubMed
  139. Atherosclerosis. 2004 Dec;177(2):255-62 - PubMed
  140. Science. 2005 Jan 21;307(5708):426-30 - PubMed
  141. BMJ Open Diabetes Res Care. 2014 Apr 26;2(1):e000017 - PubMed
  142. Circ Res. 2004 Sep 17;95(6):568-78 - PubMed
  143. J Huazhong Univ Sci Technolog Med Sci. 2007 Jun;27(3):248-51 - PubMed
  144. FEBS J. 2009 Sep;276(17):4752-62 - PubMed
  145. PLoS One. 2012;7(12):e50117 - PubMed
  146. Curr Opin Lipidol. 2007 Jun;18(3):240-5 - PubMed
  147. J Clin Invest. 2007 Jan;117(1):175-84 - PubMed
  148. Metabolism. 1994 Feb;43(2):257-62 - PubMed
  149. Metabolism. 2010 Jan;59(1):93-9 - PubMed
  150. Prog Lipid Res. 2009 Sep;48(5):275-97 - PubMed
  151. Biomed Res Int. 2014;2014:751930 - PubMed
  152. J Biol Chem. 2003 Nov 21;278(47):46654-60 - PubMed
  153. Nat Rev Immunol. 2004 May;4(5):371-9 - PubMed
  154. FASEB J. 2000 Jul;14(10):1345-51 - PubMed
  155. Eur J Clin Invest. 2012 Dec;42(12):1287-94 - PubMed
  156. Pharmacotherapy. 2000 Mar;20(3):270-9 - PubMed
  157. Lipids Health Dis. 2010 Jul 20;9:75 - PubMed
  158. Metabolism. 2004 Apr;53(4):430-4 - PubMed
  159. Can J Cardiol. 2016 Oct;32(10S2):S349-S357 - PubMed
  160. Diabetes Care. 2013 May;36(5):1074-82 - PubMed
  161. Pharmacology. 2009;84(5):282-7 - PubMed
  162. Exp Clin Cardiol. 2002 Spring;7(1):40-53 - PubMed
  163. Mol Cell Endocrinol. 2015 Feb 15;402:86-94 - PubMed
  164. Diabetes. 2014 Nov;63(11):3742-7 - PubMed
  165. Atherosclerosis. 2010 Sep;212(1):131-8 - PubMed
  166. Diabetes. 2009 Jan;58(1):46-53 - PubMed
  167. Mol Cell Endocrinol. 2015 Jan 5;399:373-85 - PubMed
  168. J Biol Chem. 2003 Jan 31;278(5):2896-902 - PubMed
  169. Biochem Biophys Res Commun. 2014 Apr 25;447(1):51-6 - PubMed
  170. Prog Mol Biol Transl Sci. 2015 ;135:175-201 - PubMed
  171. Acta Physiol (Oxf). 2014 Apr;210(4):733-53 - PubMed
  172. Am J Physiol Endocrinol Metab. 2011 Jun;300(6):E1012-21 - PubMed
  173. Chin Med J (Engl). 2014;127(16):2953-9 - PubMed
  174. PLoS One. 2014 Jun 13;9(6):e99245 - PubMed
  175. Cell Immunol. 2005 Nov;238(1):19-30 - PubMed
  176. J Am Coll Cardiol. 2013 May 14;61(19):1956-61 - PubMed
  177. Int J Obes Relat Metab Disord. 2004 May;28(5):719-25 - PubMed
  178. Joint Bone Spine. 2008 Dec;75(6):696-701 - PubMed
  179. Diabetologia. 2015 Sep;58(9):2124-32 - PubMed
  180. J Electrocardiol. 2007 Nov-Dec;40(6 Suppl):S118-22 - PubMed
  181. FEBS Lett. 2008 Aug 20;582(19):2965-72 - PubMed
  182. Diabetes. 2001 Aug;50(8):1883-90 - PubMed
  183. Arch Intern Med. 1994 Jul 25;154(14):1557-9 - PubMed
  184. PLoS One. 2015 May 26;10(5):e0126119 - PubMed
  185. J Physiol Pharmacol. 2013 Jun;64(3):281-8 - PubMed
  186. Biochem Biophys Res Commun. 2003 Aug 29;308(3):458-62 - PubMed
  187. Atherosclerosis. 2008 Jan;196(1):114-21 - PubMed
  188. Pharmacology. 2006;76(1):34-9 - PubMed
  189. FASEB J. 2004 May;18(7):908-10 - PubMed
  190. Hormones (Athens). 2006 Oct-Dec;5(4):259-69 - PubMed
  191. J Cell Physiol. 2018 Jan;233(1):153-161 - PubMed
  192. Cytokine. 2012 Oct;60(1):150-6 - PubMed
  193. J Nutr Biochem. 2015 May;26(5):563-70 - PubMed
  194. Clin Chim Acta. 2003 Oct;336(1-2):103-8 - PubMed
  195. J Biol Chem. 2012 Feb 24;287(9):6421-30 - PubMed

Publication Types